Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.49 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.44 |
| ▸ | KCNK13 | Q9HB14 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | GNRHR | P30968 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201635 | 0.86 | ESR1 (0.46) | KCNK13P2RX7KDM4EALDH1A1 | |
| SCHEMBL5203544 | 0.81 | TLR8 (0.41) | KCNK13GNRHRPKMALDH1A1 | |
| SCHEMBL29996045 | 0.79 | KCNK13 (0.48) | GABRA1GABRA5GRIN1GRIN2BKCNK13 | |
| SCHEMBL26921956 | 0.79 | KCNK13 (0.48) | GABRA1GABRA5GRIN1GRIN2BKCNK13 | |
| SCHEMBL5202670 | 0.79 | TLR8 (0.39) | KCNK13GNRHRALDH1A1 | |
| SCHEMBL5201108 | 0.79 | CYP11B2 (0.50) | KCNK13TLR7CYP11B2KDM4E | |
| SCHEMBL5204479 | 0.77 | MAPT (0.46) | KCNK13PKMALDH1A1 | |
| SCHEMBL29995644 | 0.77 | KCNK13 (0.61) | GABRA1GABRA5KCNK13TLR7CYP11B2 | |
| SCHEMBL26921332 | 0.77 | KCNK13 (0.61) | GABRA1GABRA5KCNK13TLR7CYP11B2 | |
| SCHEMBL29995628 | 0.76 | KCNK13 (0.42) | GABRA1GABRA5GRIN1GRIN2BKCNK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1210336-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US HEALTH (US) | 2007-04-25 | — | — | EP | disclosed |
| US-6894068-B2 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-05-17 | — | — | US | disclosed |
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | MICHEJDA CHRISTOPHER J (US) | 2003-10-09 | — | — | US | disclosed |
| EP-0963371-B1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | US GOV HEALTH & HUMAN SERV (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6369235-B1 | INHIBITORS OF HIV REVERSE TRANSCRIPTION FOR TREATMENT OF AIDS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191160-A1 | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase | SAMHD1, DUT, TYMP | GABRA1 2791/4885GABRA5 2482/4885GRIN1 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.